Precision medicine, often known as personalized medicine, holds significant potential in the treatment of oncological disorders. Precision medicine refers to the development of tailored therapies by utilizing genomic information, environmental factors, and the patient’s lifestyle.
With the rise of high throughput technologies, including artificial intelligence, big data analytics, and next-generation sequencing, along with the availability of patient databases, precision oncology has achieved success in improving patient outcomes.
Alongside the development of tailored medicines, several clinicians have taken a shift from a one-size-fits-all approach to personalized medicine to treat patients suffering from different forms of cancer. Research for the development of precision medicine has increased as well, and new opportunities in this field to treat multiple forms of cancer are anticipated.
According to the Roots Analysis report, the global oncology precision medicine market is growing exponentially; it is estimated to be worth USD 130 billion in 2023 and is anticipated to reach USD 364 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 8.93% during the forecast period.
Global Oncology Precision Medicine Market Outlook
The field of oncology precision medicine is one of the leading growing segments in the healthcare sector. According to the Roots Analysis report, close to 125 precision medicine oncology companies with the required expertise to develop personalized treatments for oncology are active in this area. More than 145 personalized medicines have been successfully commercialized to target different forms of cancer indications. As the key market players work to find precision medicines and alternative treatments to treat oncological disorders, the focus on tailored drugs will likely become more intense.
The top market players that have adopted advanced technology to develop precision medicines are AbbVie, Anticancer Bioscience, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Hutchmed, IDEAYA Biosciences, Johnson & Johnson Innovative Medicine, Merck, Novartis, Pfizer and Repare Therapeutics.
Precision Oncology Medicine Market: Regional Insight
According to the recent research conducted by Roots Analysis, North America is dominating the oncology precision medicine market and is anticipated to capture 46.36% of the share by 2035. In Asia-Pacific, the market is estimated to grow at a higher (CAGR) of 9.99% from 2023-2035.
Advanced Treatments for Lung Cancer
Precision medicine for oncology had its first breakthroughs in lung cancer when it targeted a specific histologic subtype of lung cancer known as non-small cell lung cancer. Non-small cell lung cancer treatment options include lorlatinib for ALK-positive mutations, osimertinib for EGFR mutants, and adagrasib for resistant KRAS mutations. Melanoma targets for BRAF mutations developed, and this solid tumor evolved into highly responsive immunotherapy approaches such as the immune checkpoint inhibitors nivolumab and ipilimumab, also known as PD-1 inhibitors, since they eliminate the inability of cytotoxic T cells to attack foreign antigens on cancer cells.
Improving Predictive Indicators in Cancer Care
With advanced technologies such as liquid biopsy and genome profiling, researchers are able to examine a tumor’s genetic makeup to develop personalized medicine. The evolving trend in personalized medicine and prognosis allows in-depth analysis of specific mutations that result in cancer, setting the groundwork for predictive indicators.
Predictive indicators such as minimal residual disease and PD-L1 status have become important in assisting cancer patients and providers in managing the disease’s genotypic and phenotypic complexity. The FDA has approved the companion diagnostics for HER-2 antibodies in breast cancer alongside Herceptin to identify the existence of the mutation and enhance results. Furthermore, diagnostic methods were used extensively for the prediction of therapies for breast cancer, such as OncotypeDx.
Possible Challenges in Precision Medicine Oncology
Despite the positive outcomes and increasing research activities on precision medicine in oncology, the field witnessed several challenges. Some of the potential challenges include the high cost of genomic profiling, ethical considerations, and the requirement for standardized guidelines to interpret genomic data. Many forms of cancer do not have well-defined genetic targets, which makes it difficult for researchers to develop precision medicine for specific types of tumors.
In conclusion, precision medicine in oncology has been fueled by the technological advancements that help researchers gain better genomic insights and develop therapies, anticipating reshaping the oncology field. Furthermore, advances in technologies such as machine learning and artificial intelligence are anticipated to improve complex genomic data interpretation, allowing researchers to identify therapeutic targets more efficiently. A collaborative approach has been followed by several oncology precision medicine market players and industrial stakeholders to drive the field forward and develop personalized medicines to treat cancer patients.
For more information, please read the full report Precision Oncology Medicine Market, which details this market’s unique dynamics, providing insights into the historic period (2022-2023) and forecasting trends for 2022-2027 and 2032.
About Author
Nancy Kapila is an accomplished pharmaceutical consultant with a rich and diverse experience spanning more than five years. Throughout her professional journey, Nancy’s expertise in providing valuable insights and strategic guidance helped clients to make informed, data-driven decisions. What sets Nancy apart is her unwavering commitment to staying at the forefront of the ever-evolving pharmaceutical landscape.
About Roots Analysis
Roots Analysis is a global leader in pharma and biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for more than a decade, Roots Analysis offers a highly analytical and data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by this firm are structured in a way that enables the reader to develop a thorough perspective on the given subject.
